Straits Times Index
3,090.31 +17.32 (+0.56%) Nikkei
33,431.51 -55.38 (-0.17%) Hang Seng
16,830.30 -212.58 (-1.25%) FTSE 100
7,529.35 +75.60 (+1.01%) Bitcoin USD
39,402.70 +594.02 (+1.53%) CMC Crypto 200
802.76 +11.20 (+1.41%)
VRTX Jan 2024 195.000 put
| Previous close | 0.2800 |
| Open | 0.2800 |
| Bid | 0.0000 |
| Ask | 4.3000 |
| Strike | 195.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.2500 - 2.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
Motley Fool5 Top Stocks to Buy Before 2024
One area to focus on is companies that generally offer steady earnings growth over time. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge milestone, and another may be just ahead. The company recently won the world's first authorization for a CRISPR-based gene-editing treatment when the U.K. gave the nod to exa-cel (to be commercialized as Casgevy).
Motley FoolCould CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. Vertex is a much larger company with proven innovative abilities, and it has generated strong and consistent revenue, earnings, and stock-market performance in the past decade. CRISPR is a much younger company with a much shorter track record, but could it one day become as successful as its larger partner?
CNW GroupHealth Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for the expanded use of PrKALYDECO® (ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 2 months and older weighing at least 3 kg who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or R117H.
